Brokerages Expect Mustang Bio Inc (NASDAQ:MBIO) Will Announce Earnings of -$0.27 Per Share
Analysts forecast that Mustang Bio Inc (NASDAQ:MBIO) will post earnings of ($0.27) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Mustang Bio’s earnings, with estimates ranging from ($0.28) to ($0.26). Mustang Bio posted earnings per share of ($0.28) during the same quarter last year, which would indicate a positive year over year growth rate of 3.6%. The company is expected to report its next quarterly earnings results on Tuesday, November 12th.
According to Zacks, analysts expect that Mustang Bio will report full year earnings of ($1.14) per share for the current fiscal year, with EPS estimates ranging from ($1.18) to ($1.11). For the next fiscal year, analysts expect that the firm will post earnings of ($1.11) per share, with EPS estimates ranging from ($1.33) to ($0.93). Zacks’ earnings per share averages are an average based on a survey of sell-side research analysts that cover Mustang Bio.
Mustang Bio (NASDAQ:MBIO) last released its earnings results on Friday, August 9th. The company reported ($0.29) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.24) by ($0.05).
Institutional investors and hedge funds have recently modified their holdings of the stock. Geode Capital Management LLC lifted its holdings in shares of Mustang Bio by 4.1% in the 4th quarter. Geode Capital Management LLC now owns 170,217 shares of the company’s stock worth $500,000 after purchasing an additional 6,741 shares in the last quarter. FNY Investment Advisers LLC bought a new position in Mustang Bio during the 2nd quarter valued at $736,000. Quinn Opportunity Partners LLC bought a new position in Mustang Bio during the 2nd quarter valued at $131,000. National Asset Management Inc. lifted its stake in Mustang Bio by 31.0% during the 2nd quarter. National Asset Management Inc. now owns 107,874 shares of the company’s stock valued at $397,000 after acquiring an additional 25,549 shares in the last quarter. Finally, Acadian Asset Management LLC bought a new position in Mustang Bio during the 2nd quarter valued at $364,000. Institutional investors own 26.90% of the company’s stock.
Shares of Mustang Bio stock traded down $0.17 on Monday, reaching $4.36. 14,819 shares of the company’s stock were exchanged, compared to its average volume of 522,799. The company has a market capitalization of $172.32 million, a P/E ratio of -3.81 and a beta of 2.13. Mustang Bio has a 52 week low of $2.18 and a 52 week high of $10.20. The firm’s 50-day moving average is $3.62 and its two-hundred day moving average is $3.75. The company has a debt-to-equity ratio of 0.21, a quick ratio of 13.10 and a current ratio of 13.10.
About Mustang Bio
Mustang Bio, Inc, a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.
Recommended Story: Technical Indicators – What is a Golden Cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mustang Bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mustang Bio and related companies with MarketBeat.com's FREE daily email newsletter.